Motif (LON:MTFB)‘s stock had its “buy” rating reaffirmed by analysts at Northland Securities in a report released on Friday.
Several other brokerages also recently issued reports on MTFB. Peel Hunt reiterated a “buy” rating and issued a GBX 108 ($1.47) price target on shares of Motif in a report on Thursday, February 1st. Northland Capital Partners reiterated a “buy” rating and issued a GBX 115 ($1.56) price target on shares of Motif in a report on Friday, May 4th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Motif currently has an average rating of “Buy” and a consensus target price of GBX 109.20 ($1.48).
Shares of Motif opened at GBX 32.70 ($0.44) on Friday, according to Marketbeat Ratings. Motif has a 12-month low of GBX 23.50 ($0.32) and a 12-month high of GBX 51.75 ($0.70).
Motif Company Profile
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus.
Receive News & Ratings for Motif Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif and related companies with MarketBeat.com's FREE daily email newsletter.